TargetMol

Torin 1

Product Code:
 
TAR-T6045
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6045-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6045-5mg5mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6045-10mg10mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6045-50mg50mg£337.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6045-100mg100mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K.
CAS:
1222998-36-8
Formula:
C35H28F3N5O2
Molecular Weight:
607.637
Pathway:
DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling; Autophagy
Purity:
0.9938
SMILES:
CCC(=O)N1CCN(CC1)c1ccc(cc1C(F)(F)F)-n1c2c(ccc1=O)cnc1ccc(cc21)-c1cnc2ccccc2c1
Target:
DNA-PK; PI3K; mTOR; Autophagy

References

Mitra D, Vega?Rubin?de?Celis S, Royla N, et al. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. International Journal of Cancer. 2021 Apr 15;148(8):1993-2009. Dowling RJ, et al, Science, 2010, 328(5982), 1172-1176. Mitra D, Vega?Rubin?de?Celis S, Royla N, et al. Abrogating GPT2 in triple negative breast cancer inhibits tumor growth and promotes autophagy[J]. International Journal of Cancer. Thoreen CC, et al, J Biol Chem, 2009, 284(12), 8023-8032. Mitra D, Vega?Rubin?de?Celis S, Royla N, et al. Abrogating GPT2 in triple?negative breast cancer inhibits tumor growth and promotes autophagy[J]. International Journal of Cancer. 2021, 148(8): 1993-2009. Lu X Y, Shi X J, Hu A, et al. Feeding induces cholesterol biosynthesis via the mTORC1?USP20?HMGCR axis. Nature. 2020, 588(7838): 479-484. Liu Q, et al, J Med Chem, 2010, 53(19), 7146-7155. Sun C Y, Li Y Z, Cao D, et al. Rapamycin and trametinib: a rational combination for treatment of NSCLC. International Journal of Biological Sciences. 2021, 17(12): 3211-3223. Lu X Y, Shi X J, Hu A, et al. Feeding induces cholesterol biosynthesis via the mTORC1?USP20?HMGCR axis[J]. Nature. 2020, 588(7838): 479-484. Li J, et al, Am J Physiol Cell Physiol, 2011, 301(1), C213-C226. Huang Z, Zhu S, Han Z, et al.Proteome-Wide Analysis Reveals TFEB Targets for Establishment of a Prognostic Signature to Predict Clinical Outcomes of Colorectal Cancer.Cancers.2023, 15(3): 744. Zheng J, Deng Y, Wei Z, et al.Lipid phosphatase SAC1 suppresses hepatitis B virus replication through promoting autophagic degradation of virions.Antiviral Research.2023: 105601.